BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 23,700 shares, a decrease of 57.8% from the February 13th total of 56,200 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average trading volume of 51,200 shares, the short-interest ratio is presently 0.5 days.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BCDA. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of BioCardia in a research report on Wednesday, December 18th. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th.

Insiders Place Their Bets

In related news, Director Simon H. Stertzer bought 22,753 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were acquired at an average price of $2.30 per share, with a total value of $52,331.90. Following the completion of the acquisition, the director now owns 40,602 shares in the company, valued at approximately $93,384.60. This trade represents a 127.47 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders purchased 26,353 shares of company stock valued at $60,585. 20.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioCardia

An institutional investor recently bought a new position in BioCardia stock. CM Management LLC purchased a new position in BioCardia, Inc. (NASDAQ:BCDA) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $54,000. CM Management LLC owned 0.55% of BioCardia at the end of the most recent reporting period. 20.57% of the stock is currently owned by hedge funds and other institutional investors.

BioCardia Trading Down 0.8 %

Shares of BCDA stock opened at $2.55 on Thursday. The stock has a 50 day simple moving average of $2.37 and a 200-day simple moving average of $2.42. The company has a market cap of $11.69 million, a price-to-earnings ratio of -0.61 and a beta of 1.28. BioCardia has a 12-month low of $1.63 and a 12-month high of $6.41.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.